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ABSTRACT 
The aim of this study was to examine the effect of the glaucoma medication on Choroidal Thickness (CT) in those with 
Primary Open-Angle Glaucoma (POAG) and normal cases. This prospective study included 27 patients with newly 
diagnosed POAG (group 1; 49 eyes), undergoing glaucoma treatment, and 30 patients, whose treatment was terminated 
due to misdiagnosis (group 2; 57 eyes). Choroidal thickness was measured using Enhanced Depth Imaging (EDI) with 
Spectral Domain Optical Coherence Tomography (SD-OCT) at the first visit and almost one month later. In group 1, the 
mean Sub-Foveal CT (SFCT) was 301 ± 91 µm, the mean CT was 264 ± 87 µm at the nasal point, 1 mm to the fovea, and 
271 ± 84 µm at the temporal point, 1 mm to the fovea. The second measurements were obtained as 39 ± 8.5 days after 
treatment began; the SFCT was 319 ± 85 µm (P = 0.0017), the nasal 1 mm CT was 275 ± 88 µm (P = 0.162), and the 
temporal 1mm CT was 291 ± 80 µm (P = 0.007). In group 2, the mean SFCT was 292 ± 100 µm, the nasal 1 mm CT was 
254 ± 97 µm, and the temporal 1 mm CT was 261 ± 97 µm. The second measurements were obtained 37.5 ± 5.5 days 
after the treatment ended; the SFCT was 295 ± 107 µm (P = 0.212), the nasal 1 mm CT was 262 ± 104 µm (P = 0.709), and 
the temporal 1 mm CT was 266 ± 104 µm (P = 0.792). Glaucoma medication affects the CT as a marker for choroidal 
blood flow in patients with glaucoma. Further studies with larger sample sizes are required to examine each glaucoma 
medication subgroup. 
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INTRODUCTION
Glaucoma is a significant cause of blindness in many 
countries, irrespective of their development status. 
Typical morphologic changes in the Optic Nerve Head 
(ONH) occur after damage to the ganglion cells and their 
axons, and this is known as Glaucomatous Optic 
Neuropathy (GON) [1-4]. Progressive changes in the optic 
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disc, retinal nerve fiber layer, and ganglion cell-inner 
plexiform layer, peripheral and central visual fields are 
perceived in GON. Intraocular Pressure (IOP) is majorly 
accepted as a significant risk factor in glaucoma, and 
although the progression of vision and visual field loss 
can be slowed or stopped by IOP reduction, in Normal-
Tension Glaucoma (NTG), it may persist regardless of 
whether IOP is medically or surgically controlled. This 
indicates that mechanisms beyond IOP, such as 
worsening choroidal blood flow or ocular ischemia, may 
be instrumental in the deterioration of vision loss [5-10]. 
There have been conflicting results in studies that 
evaluated Choroidal Thickness (CT) in patients with 
glaucoma as a sign of choroidal blood flow, both in 
histologic and imaging studies [11-13]. Histologic studies 
can be influenced by long-term perfusion loss to the eye 
and by the sample preparation method used. Imaging is a 
prerequisite for in vivo investigations of the choroid in 
glaucoma. Enhanced Depth Imaging (EDI) technique of 
Spectral Domain Optical Coherence Tomography (SD-
OCT) instruments has resulted in improved choroid 
images [14-16]. Recently, a number of studies have 
compared CT between patients with Primary Open-Angle 
Glaucoma (POAG) and controls, yet the results have not 
been conclusive. Macular or peripapillary choroidal 
thinning in patients with POAG or NTG was reported in 
some cases yet most previous studies showed no 
significant differences between patients with glaucoma 
and healthy individuals or among those, who are thought 
to have glaucoma [17-25]. Accordingly, further studies 
examining this issue are merited. The aim of glaucoma 
medication is to lower IOP, which is a major factor in the 
pathogenesis of this condition. Future treatment 
methodologies may include vaso-protective drugs, which 
influence blood flow or neuroprotective medication. 
Choroidal thickness, a marker of choroidal flow, can be 
affected by the type of glaucoma medication 
administered [5-10]. Thus, this study evaluated the effect 
of glaucoma medication on CT, using SD-OCT, with the 
EDI technique. 
METHODS 
This prospective study consisted of 27 patients with 
newly diagnosed POAG (group 1; 49 eyes; 15 females, 12 
males), and 30 patients (group 2; 57 eyes; 19 females, 11 
males), whose glaucoma treatment was terminated due 
to the misdiagnosis of glaucoma (normal subjects). In 
group 1, Sub-Foveal Choroidal Thickness (SFCT) was 
measured before anti-glaucomatous treatment and 
approximately one month after the treatment began. In 
group 2, the SFCT was measured during anti-
glaucomatous treatment and approximately one month 
after termination of the treatment in order to wait for 
the wash-out period. The study protocol was approved 
by the Ethics Committee of Istanbul Faculty of Medicine 
and all of the patients provided an informed consent. All 
researches were conducted in accordance with the 
Declaration of Helsinki. 
The exclusion criteria for both groups were diabetes 
mellitus, systemic arterial hypertension, use of systemic 
corticosteroids, macula diseases, ocular surgery or 
trauma, inflammation, non-glaucomatous optic 
neuropathy, or corneal opacities, and smoking. Inclusion 
criteria were having a Corrected Distance Visual Acuity 
(CDVA) of      , within -5 to +3 diopters (D) of 
refractive errors, and ± 3D cylindrical correction, with a 
clear cornea and clear ocular media as well as diagnosis 
of POAG in Group 1. The inclusion criteria for Group 2 
were misdiagnosis of POAG, being under treatment of 
anti-glaucomatous medication, having a CDVA of 20/20, 
a normal-appearing optic disc, normal Retinal Nerve 
Fiber Layer (RNFL) thickness measurement, a normal 
visual field, no ocular pathology or ocular trauma, and no 
familial history of glaucoma. 
All patients underwent detailed ophthalmologic 
assessments, including quantification of CDVA, slit-lamp 
biomicroscopy, Goldmann applanation tonometry, 
gonioscopy, indirect ophthalmoscopy, RNFL thickness 
using SPECTRALIS® OCT (Heidelberg Engineering, 
Heidelberg, Germany), and achromatic automated 
perimetry, using the 30-2 Swedish Interactive Threshold 
Algorithm (SITA) standard program (Humphrey Visual 
Field Analyzer; Carl Zeiss-Meditec, Inc., Dublin, CA, USA). 
The POAG was defined as the presence of an abnormal 
glaucomatous optic disc, an abnormal visual field 
correlated with the decrease in RNFL thickness, an IOP > 
21 mm Hg (without medical treatment), and an open-
angle as determined by gonioscopy. 
Each patient was examined using SPECTRALIS HRA-OCT in 
the EDI mode. The choroid was imaged by positioning the 
SD-OCT device sufficiently close to the eye to obtain a 
clear image. Each image was averaged from 100 scans 
using the automated averaging and eye-tracking features 
provided by the SPECTRALIS HRA-OCT. The SFCT was 
measured vertically from the outer border of the hyper-
reflective band corresponding to the retina pigment 
epithelium to the inner surface of the sclera, using the 
caliper tools of the software (Heidelberg Eye Explorer 
Version 1.6.4.0; Heidelberg Engineering). Choroidal 
thickness was measured at three points: At the SFCT and 
at 1 mm nasal and 1 mm temporal to the fovea. A single 
experienced technician took all the measurements. One 
of the measurements is shown in Figure 1. All EDI-OCT 
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measurements were made in the morning in order 
obviate the effect of diurnal variation in CT. 
The statistical analyses performed using SPSS 20.0 (SPSS, 
Inc., Chicago, IL, USA). The Shapiro Wilk (SW) test was 
applied to study normality of distribution. The Wilcoxon 
test was used to verify statistically significant differences 
between the two groups. Regarding continuous 
variables, for normally distributed variables, independent 
samples t-test was used and for non-normally distributed 
variables, the Mann-Whitney U test was used. The Chi-
square test was used for categorical variables. For all 








In this prospective study, the researchers examined 106 
eyes of 57 patients (34 females and 23 males). The mean 
± Standard Deviation (SD) of age was 55.6 ± 14.7 years. 
The patients’ clinical characteristics are summarized in 
Table 1.  
In group 1 (49 eyes; 27 patients with newly diagnosed 
POAG), the mean ± SD of age of the participants was 55.6 
± 12 years. The mean spherical equivalent was -0.11 ± 1.8 
D. At the time of diagnosis, the mean IOP was 23.5 ± 1.5 
millimeters of mercury (mm Hg) and the mean average 
RNFL thickness was 92 ± 18 micrometers (µm). The mean 
± SD of SFCT was 301 ± 91 µm; at the nasal point 1 mm to 
the fovea, the mean ± SD of CT was 264 ± 87 µm, and at 
the temporal point 1 mm to the fovea, the mean ± SD of 
CT was 271 ± 84 µm.  
The glaucoma medications included prostaglandin 
analogs in 29 eyes, carbonic anhydrase inhibitors + 
timolol fixed-combinations in five eyes, brimonidine 
tartrate in two eyes, brimonidine tartrate + timolol fixed-
combination in nine eyes, and bimatoprost + timolol 
fixed-combination in four eyes. The details of the drugs 
are shown in Table 2. The second IOP and CT 
measurements were 39 ± 8.5 days after the treatment 
began. The second mean ± SD of IOP was 15.3 ± 2.4 mm 
Hg (P < 0.001). The second mean ± SD of SFCT was 319 ± 
85 µm (P = 0.0017), the mean ± SD of nasal 1 mm CT was 
275 ± 88 µm (P = 0.162), and the mean ± SD of temporal 
1 mm CT was 291 ± 80 µm (P = 0.007). The comparison of 
CT in group 1 before and after treatment is presented in 
Table 3. 
In group 2 (57 eyes and 30 patients), glaucoma treatment 
was terminated due to misdiagnosis and no other 
ophthalmologic pathologies were found. The mean ± SD 
of age of the participants was 55.6 ± 17 years. The mean 
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± SD of spherical equivalent was 0.4 ± 2.7 D. The mean ± 
SD of IOP at the time of diagnosis was 15 ± 3.2 mm Hg 
and the mean ± SD of average RNFL thickness was 102 ± 
9 µm. The mean ± SD of SFCT was 292 ± 100 µm; at the 
nasal point 1 mm to the fovea, the mean ± SD of CT was 
254 ± 97 µm and at the temporal point 1 mm to the 
fovea, the mean ± SD of CT was 261 ± 97 µm. The 
following glaucoma medications were terminated: 
Prostaglandin analogs in 32 eyes, carbonic anhydrase 
inhibitors + timolol fixed-combinations in eight eyes, 
brimonidine tartrate in three eyes, brimonidine tartrate + 
timolol fixed-combination in two eyes, prostaglandin 
analogs + timolol fixed-combination in four eyes, 
carbonic anhydrase inhibitors in two eyes, and timolol 
maleate in six eyes. The details of these drugs are shown 
in Table 2. The second IOP and CT measurements were 
obtained as 38 ± 5.5 days after treatment ended. The 
second mean ± SD of IOP was 15.5 ± 2.5 mmHg (P > 
0.001). The second mean ± SD of SFCT was 295 ± 107 µm 
(P=0.212), the mean ± SD of nasal 1 mm CT was 262 ± 
104 µm (P=0.709), and the mean ± SD of temporal 1 mm 
CT was 266 ± 104 µm (P=0.792). The comparison of CT in 
group 2 of those under treatment and without treatment 
is shown in Table 4. 
 
Table 1: Clinical Characteristics in Study Participants of both Groups (n = 106) 
 Group 1, (n=49) Group 2, (n=57) P
 
Age(y) 56 ± 12 56 ± 17 0.999 
Spherical Equivalent, D -0.11 ± 1.8 0.42 ± 2.74 0.89 
Central Corneal Thickness, µm 537 ± 37 552 ± 37 0.98 
RNFL Average Thickness, µm 92 ± 18 102 ± 9 0.007* 
Data are presented as mean ± SD. SD: standard deviation; n: number; y: year; D: diopter; µm: micrometer; RNFL: retinal nerve fiber layer.  
Note: Independent samples t test and Mann Whitney U test applied for analysis. *: P value less than 0.05. 
 
Table 2: Details of the anti-glaucoma drugs started or terminated in both groups 
Brand name Active ingredient Group1 (n=49) Group 2 (n=57) 
Lumigan® 
1 
Bimatoprost 0.01% 20 2 
Xalatan®
2 
Latanoprost 0.005% 9 27 
Travatan®
3 
Travoprost 0.004% 0 3 
Alphagan-P®
1 
Brimonidine tartrate 0.15% 2 3 
Combigan®
1 
Timolol maleate 0.5%+ brimonidine tartrate 0.2% 9 2 
Azarga®
3 
Brinzolamide 1% + timolol maleate 0.5% 3 2 
Cosopt®
4 
Dorzolamide 2% + Timolol maleate 0.5% 2 6 
Ganfort®
1 
Bimatoprost 0.001% + Timolol maleate 0.5% 4 0 
Xalacom®
2 
Latanoprost 0.005% + Timolol maleate 0.5% 0 2 
Duotrav®
3 
Travoprost 0.004%+ Timolol maleate 0.5% 0 2 
Azopt®
3 
Brinzolamide 1% 0 2 
Timoptic XE®
4 
Timolol maleate 0.5% 0 6 
1 
Allergan, Inc., Irvine, CA, USA; 
2 
Pfizer, Inc., New York, NY, USA; 
3 
Alcon laboratories, Inc., Fort Worth, TX, USA; 
4 
Merck & Co., Inc, Blue Bell, PA 
 
Table 3: Comparison of choroidal thicknesses in Group 1 before and after the treatment 
 Before treatment After treatment P
 
Choroidal thicknesses(µm ± SD)    
Subfoveal  301 ± 91 319 ± 85 0.0017* 
Nasal 1mm to fovea 264 ± 87 275 ± 88 0.162 
Temporal 1 mm to fovea 271 ± 84 291 ± 80 0.007* 
SD: standard deviation; µm: micrometer; mm:milimeter. Note: Wilcoxon test applied for analysis. *: P value less than 0.05. 
 
DISCUSSION
This study aimed at evaluating the effect of glaucoma 
medication on CT using SD-OCT with the EDI technique. 
The results indicated that the mean sub-foveal CT was 
significantly higher after topical anti-glaucomatous 
medication treatment in patients, who were newly 
diagnosed as POAG. However, there was no significant 
difference in normal subjects.  
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Numerous studies have investigated choroid in glaucoma 
by measuring CT thickness, using histopathologic or in 
vivo imaging techniques. Histologic studies have shown 
divergent CT results in post-mortem glaucoma studies 
[12, 13]. Yin et al. found a decrease in CT, which they 
attributed to the coexistence of decreased vessel density 
and the reduced patency of choroidal vessels. In 
contrast, Spraul et al. found an increase in both calibers 
of the largest choroidal arteries and in the CT [12, 13]. 
The disparity between these studies may be related to 
the methods used. 
 
Table 4: Comparison of choroidal thicknesses in Group 2 under treatment and without treatment 
 Under treatment Without treatment P
 
Choroidal thicknesses(µm ± SD)    
Subfoveal  292 ± 100 295 ± 107 0.212 
Nasal 1mm to fovea 254 ± 97 262 ± 104 0.709 
Temporal 1 mm to fovea 261 ± 97 266 ± 104 0.792 
SD: standard deviation; µm: micrometer; mm:milimeter. Note: Wilcoxon test applied for analysis. 
 
Newer techniques that can measure CT in vivo, such as 
SD-OCT, are more likely to be accurate. The SD-OCT 
coupled with a technique called EDI, which was described 
by Margolis and Spaide, has the ability to image beyond 
the retinal pigment epithelium [14, 15]. These studies 
showed that CT decreased with age, and in eyes with a 
longer axial length, the choroid was thinner. Thus, many 
studies have investigated CT within the macula because 
the choroid is thickest under the fovea in glaucomatous 
eyes. In many published studies, no meaningful 
differences were found between the macular CT of 
glaucomatous eyes in comparison with those of controls 
[20-23, 26]. Mwanza et al. studied one eye in 38 normal 
patients, 20 with NTG, and 56 with POAG and they could 
not find any relationship between glaucoma and average 
macular CT [20]. In their study, patients were also 
grouped, according to the degree of visual field change; 
nevertheless, no meaningful difference in CT was 
determined between the groups. In another study by the 
same group, the affected eyes of patients with unilateral 
advanced glaucoma were compared with their 
unaffected eyes [23].  In this way, variables, such as age 
and comorbidities, were eliminated, yet still no 
differences were found. Rhew et al. measured SFCT in 32 
patients with NTG, whose results were compared with 35 
healthy controls and they found no meaningful 
difference [22]. Jonas et al. measured CT in 71 patients 
with glaucoma and 228 normal individuals, and their 
findings revealed no significant differences [26]. Toprak 
et al. assessed CT and vessel diameter in patients with 
POAG using SD-OCT EDI mode with age-based analysis 
and compared them with healthy subjects [27]. They 
found no significant difference in CT and vessel caliber 
between patients with POAG and healthy controls. Wang 
et al. examined the CT of patients with POAG using EDI-
OCT and compared them with healthy subjects [28]. They 
also performed a meta-analysis about this among 
Chinese patients. They suggested that POAG was not 
significantly associated with a marked thinning or 
thickening of the choroid based on EDI-OCT 
measurements. The findings of the above studies are in 
contrast with the findings of the current study. The 
reason for this difference could be due to the differences 
in the race of the subjects, the course of the disease, the 
type of drugs used and other causes that are still 
unknown and should be investigated in future studies in 
details.  
In contrast, Hirooka et al. suggested that CT was focally 
diminished in patients with glaucoma [19]. The authors 
studied 62 normal eyes and 45 eyes with NTG and 
investigated the difference. They found a meaningful 
choroidal thinning in the nasal fovea of NTG patients. 
Roberts et al. compared 92 controls with glaucoma 
patients, including focal (n = 34), diffuse (n = 35), and 
sclerotic (n = 34) optic disc damage [18]. They only found 
that the choroid was thinner in eyes with sclerotic disc 
damage. Ersoz et al. investigated the difference of CT and 
factors influencing CT between POAG patients and the 
control group by using SD-OCT EDI mode [29]. They found 
that CT was thinner in the POAG group. However, this 
was suggested to arise from the difference in IOP and 
pulse rate between the groups. The findings reported in 
these studies revealed that open-angle glaucoma is not 
associated with the thickening of the choroid in the 
foveal or para-foveal region, which differs from our 
results that could be contributed to reasons mentioned 
earlier.  
The researchers aimed to study the impact of glaucoma 
medication on CT as a sign of choroidal flow and ocular 
perfusion. In POAG, the researchers found a significant 
difference in CT under anti-glaucomatous treatment. In 
most cases, glaucoma medication is used to lower IOP to 
protect against the deleterious effect on neuro-retinal 
tissues. Many existing medications interact with the 
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vasculature and change ocular blood flow. Many 
previous studies have examined the effect of subclasses 
of medications on ONH and retinal, choroidal, and retro-
bulbar circulation [30-43]. 
By blocking carbonic anhydrase type II, the topical 
Carbonic Anhydrase Inhibitor (CAI), dorzolamide, 
significantly lowers IOP. The efficacy of CAI, as a 
vasodilator, has been demonstrated by many studies 
[30]. Using color Doppler imaging, Martinez et al. 
evaluated the effect of dorzolamide on ocular blood flow 
in normal and glaucomatous eyes. They showed higher 
end-diastolic velocities in the ophthalmic and central 
retinal artery and also increased peak-systolic velocity in 
the central retinal artery in glaucomatous eyes [31]. 
Dorzolamide was also found to accelerate the retinal 
arteriovenous flow rate of fluorescein dye without 
affecting flow speeds in any retrobulbar vessels in 
patients with NTG [32]. Recently, it has been reported 
that another CAI brinzolamide has a better affinity. In 
rabbit studies it was shown that it is a good 
vasodilatation effect and thus results a higher blood flow 
in the ONH [33]. However, there are no data concerning 
the effects of dorzolamide and brinzolamide on choroidal 
flow or CT. 
Different studies evaluated the use of topical β-blockers 
as a local anti-glaucomatous medication. Using laser 
Doppler velocimetry, one study found that treatment 
with timolol maleate (0.5%) resulted in a substantial 
difference in retinal blood flow in healthy controls [34]. 
Conflictingly, Yoshida et al. found no difference in blood 
flow after the same treatment [35]. It might be 
considered, therefore, that these β-blocker studies were 
unpersuasive regarding drug penetration and their 
effects on ocular blood flow [36].  
Another group of drugs that might be considered for 
their possible vasoactive effects are alpha-adrenergic 
agonists. Using laser Doppler flow metry, Carlsson et al. 
showed that topical brimonidine has no retinal blood 
flow alteration [37]. The literature includes studies that 
found that brimonidine tartrate had no impact on ocular 
hemodynamics, which may be because of the very slight 
penetration to the posterior pole [38]. 
The mechanism of action of prostaglandin analogs, 
through increasing uveoscleral outflow, subsequently 
reduces IOP. Using scanning laser Doppler flowmetry, 
two hours and 24 hours after administration of 
latanoprost drops (0.005%) in healthy volunteers, Seong 
et al. reported no meaningful difference in the ONH and 
peripapillary retinal blood flow [39]. In contrast, other 
studies with pulsatile Ocular Blood Flow (pOBF) 
measured a positive effect on ONH blood flow [40, 41]. 
Vetrugno et al. used pOBF to study the contrast in the 
effects of bimatoprost and timolol on IOP and choroidal 
blood flow in POAG patients and found that bimatoprost 
increased blood flow [42]. Koz et al. used color Doppler 
ultrasound to investigate the effect of three 
prostaglandin analogs (latanoprost, travoprost, and 
bimatoprost) on retro-bulbar blood flow velocity in 
previously untreated POAG or Ocular Hypertension (OHT) 
patients [43]. Their results suggested that the three 
prostaglandin analogs meaningfully reduced IOP and 
increased ocular perfusion pressure in all patients. 
Topical travoprost and latanoprost significantly reduced 
the resistive index of the central retinal artery and 
ophthalmic artery, respectively. However, the authors 
observed that topical bimatoprost did not influence 
ocular hemodynamics [43]. 
In summary, all these studies showed that the effect of 
glaucoma medications on ocular, retinal, or choroidal 
blood flow is still controversial. Moreover, there are no 
data on the effect of these medications on CT. The 
current study aimed at identifying the effect of anti-
glaucomatous medication on CT using SD-OCT in EDI 
mode. In group one, the patients were newly diagnosed 
as having POAG and the mean sub-foveal CT was 
significantly higher after a treatment period of 
approximately 40 days, as shown in Table 3. In group 2, 
the patients were misdiagnosed as having glaucoma, 
thus their treatments were terminated. Therefore, it 
could be suggested that group 2 was a control group. 
There was no significant difference in the mean CT in 
group 2 after the wash-out period, as shown in Table 4. 
The present study had many limitations. First, the sample 
size of the two groups was relatively small. Second, the 
type of glaucoma medication that was administered was 
not the same for each patient or each group. It would be 
better to examine each subgroup of anti-glaucomatous 
medication in the same patients because there can be 
differences based on the type of medications used. Third, 
this study only measured CT in the subfoveal region and 
the parafoveal area, and did not measure peripapillary 
CT, which is suggested to have a greater association with 
glaucoma. Fourth, the measurements were taken by a 
single technician with a manual caliper. In conclusion, the 
current study showed that glaucoma medication affects 
CT as a marker for choroidal blood flow in patients with 
glaucoma. Drugs that influence blood flow, thereby act 
as vasoprotective and neuroprotective medications, and 
might be options to investigate in the future. Thus, 
additional studies with larger sample sizes are needed to 
examine each glaucoma medication subgroup and should 
include a longer follow-up period. 
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